Correction: CDK5 activator protein p25 preferentially binds and activates GSK3β (Proc Natl Acad Sci USA (2014) 111, (E4887-E4895) 10.1073/pnas.1402627111);CDK5 activator protein p25 preferentially binds and activates GSK3β

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 45, 2014, Pages E4887-E4895

  Chow, Hei Man ^a   Guo, Dong ^b   Zhou, Jie Chao ^b   Zhang, Guan Yun ^b   Li, Hui Fang ^b   Herrup, Karl ^a,c   Zhang, Jie ^b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b XIAMEN UNIVERSITY   (China)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

GSK3 ; Neurodegeneration; P25; Tau; catenin

Indexed keywords

AXIN; BETA CATENIN; CALPAIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN P25; PROTEIN P35; SMALL INTERFERING RNA; TAU PROTEIN; APC PROTEIN; CDK5 PROTEIN, MOUSE; CDK5R1 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MULTIPROTEIN COMPLEX; PHOSPHOTRANSFERASE; PROTEIN BINDING;

AGED; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MOLECULAR DOCKING; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; DEGENERATIVE DISEASE; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; AXIN PROTEIN; BETA CATENIN; CYCLIN-DEPENDENT KINASE 5; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; NEURODEGENERATIVE DISEASES; NEURONS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEIN BINDING;

EID: 84909606335     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510490112     Document Type: Erratum

References (61)

1. Ashford JW (2004) APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 23(3):157-165.
2. Budson AE, Price BH (2005) Memory dysfunction. N Engl J Med 352(7):692-699.
3. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 10(2):184-192.
4. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
5. Terry RD, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572-580.
6. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27(5):457-464.
7. Cruz JC, et al. (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26(41):10536-10541.
8. Baum L, Hansen L, Masliah E, Saitoh T (1996) Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol Chem Neuropathol 29(2-3):253-261.
9. Dhavan R, Tsai LH (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2(10):749-759.
10. Tang X, et al. (2005) Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci 25(19):4823-4834.
11. Smith DS, Greer PL, Tsai LH (2001) Cdk5 on the brain. Cell Growth Differ 12(6):277-283.
12. Cicero S, Herrup K (2005) Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci 25(42):9658-9668.
13. Zhang J, et al. (2008) Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons. Proc Natl Acad Sci USA 105(25):8772-8777.
14. Turner NC, et al. (2008) A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27(9):1368-1377.
15. O'Hare MJ, et al. (2005) Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 25(39):8954-8966.
16. Zhang J, et al. (2010) Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 30(15):5219-5228.
17. Patrick GN, et al. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762):615-622.
18. Ahlijanian MK, et al. (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97(6):2910-2915.
19. Wen Y, et al. (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28(10):2624-2632.
20. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104(6):1433-1439.
21. Hur EM, Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11(8):539-551.
22. Kim YT, Hur EM, Snider WD, Zhou FQ (2011) Role of GSK3 signaling in neuronal morphogenesis. Front Mol Neurosci 4:48.
23. Alabed YZ, Pool M, Ong Tone S, Sutherland C, Fournier AE (2010) GSK3 beta regulates myelin-dependent axon outgrowth inhibition through CRMP4. J Neurosci 30(16):5635-5643.
24. Peineau S, et al. (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(Suppl 1):S428-S437.
25. O'Brien WT, et al. (2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24(30):6791-6798.
26. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR (1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12(2):803-808.
27. Rubinfeld B, et al. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272(5264):1023-1026.
28. Pei JJ, et al. (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58(9):1010-1019.
29. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281(35):25457-25465.
30. Guidato S, McLoughlin DM, Grierson AJ, Miller CC (1998) Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem 70(1):335-340.
31. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934.
32. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6(6):464-479.
33. Lacy ER, et al. (2005) Molecular basis for the specificity of p27 toward cyclindependent kinases that regulate cell division. J Mol Biol 349(4):764-773.
34. Ponsioen B, et al. (2004) Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 5(12):1176-1180.
35. Tang D, Chun AC, Zhang M, Wang JH (1997) Cyclin-dependent kinase 5(Cdk5) activation domain of neuronal Cdk5 activator. Evidence of the existence of cyclin fold in neuronal Cdk5a activator. J Biol Chem 272(19):12318-12327.
36. Chou KC, Watenpaugh KD, Heinrikson RL (1999) A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun 259(2):420-428.
37. Comeau SR, Gatchell DW, Vajda S, Camacho CJ (2004) ClusPro: A fully automated algorithm for protein-protein docking. Nucleic Acids Res 32(web server issue):W96-99.
38. Tarricone C, et al. (2001) Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell 8(3):657-669.
39. Dajani R, et al. (2003) Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 22(3):494-501.
40. Weihl CC, et al. (1999) Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci 19(13):5360-5369.
41. ter Haar E, et al. (2001) Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8(7):593-596.
42. Taelman VF, et al. (2010) Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143(7):1136-1148.
43. Farago M, et al. (2005) Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 65(13):5792-5801.
44. Crespo-Biel N, Camins A, Canudas AM, Pallàs M (2010) Kainate-induced toxicity in the hippocampus: Potential role of lithium. Bipolar Disord 12(4):425-436.
45. Goedert M (2004) Tau protein and neurodegeneration. Semin Cell Dev Biol 15(1):45-49.
46. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharideinduced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25(39):8843-8853.
47. Green KN, et al. (2008) Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 28(45):11500-11510.
48. Li HL, et al. (2007) Phosphorylation of tau antagonizes apoptosis by stabilizing betacatenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci USA 104(9):3591-3596.
49. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149(6):1192-1205.
50. Seira O, et al. (2010) Neurites regrowth of cortical neurons by GSK3beta inhibition independently of Nogo receptor 1. J Neurochem 113(6):1644-1658.
51. Yamaguchi H, et al. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92(3):232-241.
52. Pei JJ, et al. (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56(1):70-78.
53. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33(1):43-55.
54. Blalock EM, et al. (2004) Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101(7):2173-2178.
55. Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30(11):630-641.
56. Lee MS, et al. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405(6784):360-364.
57. Giusti-Rodríguez P, et al. (2011) Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of β-secretase (BACE1). J Neurosci 31(44):15751-15756.
58. Fukumoto S, et al. (2001) Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 276(20):17479-17483.
59. Zhang J, Li H, Herrup K (2010) Cdk5 nuclear localization is p27-dependent in nerve cells: Implications for cell cycle suppression and caspase-3 activation. J Biol Chem 285(18):14052-14061.
60. Fang WQ, Chen WW, Fu AK, Ip NY (2013) Axin directs the amplification and differentiation of intermediate progenitors in the developing cerebral cortex. Neuron 79(4):665-679.
61. Comeau SR, Gatchell DW, Vajda S, Camacho CJ (2004) ClusPro: An automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20(1):45-50.